{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:19:38Z","timestamp":1791047978073,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.cgh.2016.06.025","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T18:14:50Z","timestamp":1467742490000},"page":"25-36.e27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"15","author":[{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"G\u00f3mez-Ulloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2016.06.025_bib1","doi-asserted-by":"crossref","first-page":"17463","DOI":"10.3748\/wjg.v20.i46.17463","article-title":"Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients","volume":"20","author":"Zippi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/00365521.2014.991752","article-title":"Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort","volume":"50","author":"Isene","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib4","doi-asserted-by":"crossref","first-page":"12269","DOI":"10.3748\/wjg.v20.i34.12269","article-title":"Smoking increases the risk of extraintestinal manifestations in Crohn's disease","volume":"20","author":"Ott","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib5","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1023\/A:1026650719552","article-title":"Osteoporosis and determinants of bone density in patients with Crohn's disease","volume":"43","author":"Robinson","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2016.06.025_bib6","first-page":"41","article-title":"Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors","volume":"24","author":"Koutroubakis","year":"2011","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000092013","article-title":"Analysis of risk factors for low bone mineral density in inflammatory bowel disease","volume":"73","author":"Frei","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2016.06.025_bib8","first-page":"43","article-title":"Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort","volume":"232","author":"Schoon","year":"2000","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.cgh.2016.06.025_bib9","first-page":"21","article-title":"Management of cutaneous disorders related to inflammatory bowel disease","volume":"25","author":"Pellicer","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib10","doi-asserted-by":"crossref","first-page":"13501","DOI":"10.3748\/wjg.v20.i37.13501","article-title":"Pulmonary manifestations of inflammatory bowel disease","volume":"20","author":"Ji","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040622314563929","article-title":"Management of arthropathy in inflammatory bowel diseases","volume":"6","author":"Peluso","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2016.06.025_bib12","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/S1873-9946(13)60660-1","article-title":"P639 influence of extraintestinal manifestations in health-related quality of life in inflammatory bowel disease patients","volume":"7","author":"Barreiro-de Acosta","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2016.06.025_bib13","doi-asserted-by":"crossref","first-page":"A-355","DOI":"10.1016\/S0016-5085(09)61629-2","article-title":"M1126 extraintestinal manifestations of inflammatory bowel disease and their impact on quality of life: results from the European Collaborative Study of Inflammatory Bowel Disease (EC-IBD)","volume":"136","author":"Isene","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.06.025_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2016.06.025_bib15","first-page":"890","article-title":"Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease","volume":"16","author":"Andrisani","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cgh.2016.06.025_bib16","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ibd.20196","article-title":"Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease","volume":"13","author":"Barrie","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.06.025_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.12998\/wjcc.v1.i2.74","article-title":"Biological therapy for dermatological manifestations of inflammatory bowel disease","volume":"1","author":"Zippi","year":"2013","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.cgh.2016.06.025_bib18","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2174\/1389450115666140908125453","article-title":"Biologics for extraintestinal manifestations of IBD","volume":"15","author":"Vavricka","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.cgh.2016.06.025_bib19","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2016.06.025_bib20","series-title":"Undertaking systematic reviews of research on effectiveness. CRD Report 4","year":"2001"},{"key":"10.1016\/j.cgh.2016.06.025_bib21","unstructured":"National Heart Lung and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. Available at: http:\/\/www.nhlbi.nih.gov\/health-pro\/guidelines\/in-develop\/cardiovascular-risk-reduction\/tools\/cohort. Accessed June 1,\u00a02016."},{"key":"10.1016\/j.cgh.2016.06.025_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.06.025_bib23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","article-title":"The effect of infliximab on extraintestinal manifestations of Crohn's disease","volume":"25","author":"Kaufman","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cgh.2016.06.025_bib24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ibd.21836","article-title":"Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial","volume":"18","author":"Rubin","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.06.025_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.06.025_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease","volume":"34","author":"Rispo","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.cgh.2016.06.025_bib27","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","article-title":"Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease","volume":"97","author":"Herfarth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib28","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","article-title":"Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations","volume":"63","author":"Generini","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2016.06.025_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.21663","article-title":"Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE","volume":"18","author":"L\u00f6fberg","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.06.025_bib30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","article-title":"Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease","volume":"104","author":"Barreiro-de-Acosta","year":"2012","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.cgh.2016.06.025_bib31","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s10620-015-3606-z","article-title":"Adalimumab therapy has a beneficial effect on bone metabolism in patients with Crohn's disease","volume":"60","author":"Veerappan","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2016.06.025_bib32","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2005.50219.x","article-title":"Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease","volume":"100","author":"Bernstein","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1155\/2007\/216162","article-title":"Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients","volume":"21","author":"Mauro","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1196\/annals.1346.055","article-title":"The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease","volume":"1068","author":"Pazianas","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cgh.2016.06.025_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.mcg.0000190762.80615.d4","article-title":"Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease","volume":"40","author":"Abreu","year":"2006","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2036.2004.02152.x","article-title":"Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease","volume":"20","author":"Franchimont","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.06.025_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2004.02097.x","article-title":"Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study","volume":"20","author":"Ryan","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.06.025_bib38","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/MIB.0000000000000417","article-title":"The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease","volume":"21","author":"Koutroubakis","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.06.025_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.2009.009985","article-title":"Prevalence and pathogenesis of anaemia in inflammatory bowel disease: influence of anti-tumor necrosis factor-alpha treatment","volume":"95","author":"Bergamaschi","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cgh.2016.06.025_bib40","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","article-title":"Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease","volume":"58","author":"Arg\u00fcelles-Arias","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2016.06.025_bib41","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib42","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/MEG.0000000000000133","article-title":"Coagulation state in patients with Crohn's disease: the effect of infliximab therapy","volume":"26","author":"Wang","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.06.025_bib43","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MIB.0000000000000301","article-title":"Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study","volume":"21","author":"Bollen","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.06.025_bib44","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.cgh.2008.05.010","article-title":"Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality","volume":"6","author":"Caspersen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.06.025_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/01.MIB.0000480260.28955.65","article-title":"The effect of vedolizumab on extraintestinal manifestations in patients with Crohn\u2019s disease in GEMINI 2","volume":"22","author":"Rubin","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.06.025_bib46","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/ajg.2015.355","article-title":"Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease","volume":"110","author":"Hirten","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.06.025_bib47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S0266462312000086","article-title":"The effect of English-language restriction on systematic review-based meta-analyses:\u00a0a systematic review of empirical studies","volume":"28","author":"Morrison","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.cgh.2016.06.025_bib48","author":"Berkman","year":"2013"},{"key":"10.1016\/j.cgh.2016.06.025_bib49","author":"Balshem","year":"2013"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651630372X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651630372X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:21:39Z","timestamp":1761542499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235651630372X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S154235651630372X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2016.06.025","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2016.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute","name":"copyright","label":"Copyright"}]}}